The research and development (R&D) facility is expected to take shape in the next 18 to 24 months,” said Anand Budhraja, general manager, Amway India.
On the sidelines of the launch of Amway’s product All Plant Protien Power in Chennai, Budhraja said: “We are planning to set up a high-end R&D centre at Nilakottai, near Madurai, where around 50 acre land is available. A manufacturing sector is coming up on 25 acres.”
Sam Rehnborg, president, Nutrilite Health Institute, said, “India has already been selected by our global research and development team as a key location which could be used as an R&D centre.” The company is looking at India as a key regional export base as well as an R&D hub.
There would be an R&D facility coming in the upcoming manufacturing centre, but the plans are to set up a high-end R&D centre which would both work with the other existing global R&D centres of Amway and also work on specific regional projects. The company, at present, has similar high-end R&D centres in the US and China. Budhraja said details, including investment and the number of scientists to be engaged, have not been finalised yet.
Amway is investing around Rs 550 crore in its facility in Nilakottai. It would start manufacturing in the third quarter of 2015.
The company is currently validating the lines and the launch of the first line of production from the facility, expected in March.
The facility would initially address the domestic market, but plans are to export products. The company is targeting to hire 500 employees at the manufacturing site, which will double its employee strength by the end of the year.
The products, including the newly launched All Plant Protien Powder, would be manufactured in the new facility. Once established, the facility have a capacity to service a $1-billion market.
The company, which closed its business at Rs 2,045 crore last year with a tapering of around five per cent, is expecting the market to be almost the same for the year or two, after which it would see the revenues doubling.
A few regulatory issues in the recent past has slowed down growth, but it would expect the government to come out with some framework in the direct selling market in the near future, said Budhraja..
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)